Diabetes, Vol 41, Issue 11 1400-1408, Copyright © 1992 by American Diabetes Association

ARTICLES

Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects

GR Fulcher, M Walker, C Catalano, L Agius and KG Alberti
Department of Medicine, Medical School, University of Newcastle Upon Tyne, United Kingdom.

NEFAs characteristically are elevated in obese NIDDM patients in both the basal state and after insulin. This elevation might aggravate glycemic control both by decreasing peripheral glucose disposal (glucose-fatty acid cycle), and by increasing HGO. Thus, lowering plasma NEFA levels might improve carbohydrate metabolism. We therefore measured HGO and fuel use (by indirect calorimetry) both in the basal state and during the last 30 min of a hyperinsulinemic clamp (0.025U.kg-1.h-1) in 8 obese NIDDM patients (BMI 34.8 +/- 1.0 kg/m2) after complete overnight suppression of plasma NEFA levels with acipimox, a new nicotinic acid analogue. After acipimox, mean basal plasma NEFA and glycerol levels were lower than control values (0.11 +/- 0.02 vs. 0.65 +/- 0.04 mM, P < 0.001; and 16 +/- 3 vs. 68 +/- 7 microM, P = 0.004, respectively) and were accompanied by a fall in lipid oxidation (acipimox vs. placebo: 16.1 +/- 1.2 vs. 38.8 +/- 2.4 mg.m-2 x min-1; P < 0.001) and a rise in glucose oxidation (91.1 +/- 6.2 vs. 54.1 +/- 9.0 mg.m-2 x min-1; P = 0.002). Basal HGO and fasting plasma glucose levels were lower (94.1 +/- 9.2 vs. 118.5 +/- 9.5 mg.m-2 x min-1, P = 0.01; and 8.3 +/- 1.2 vs. 9.8 +/- 1.2 mM; P < 0.001), respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. Lindegaard, C. Frosig, A. M. W. Petersen, P. Plomgaard, S. Ditlevsen, B. Mittendorfer, G. Van Hall, J. F.P. Wojtaszewski, and B. K. Pedersen Inhibition of Lipolysis Stimulates Peripheral Glucose Uptake but Has No Effect on Endogenous Glucose Production in HIV Lipodystrophy Diabetes, August 1, 2007; 56(8): 2070 - 2077. [Abstract] [Full Text] [PDF]

				P. E. Carey, J. Gerrard, G. W. Cline, C. Dalla Man, P. T. English, M. J. Firbank, C. Cobelli, and R. Taylor Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E941 - E947. [Abstract] [Full Text] [PDF]

				C. Anderwald, E. Bernroider, M. Krssak, H. Stingl, A. Brehm, M. G. Bischof, P. Nowotny, M. Roden, and W. Waldhausl Effects of Insulin Treatment in Type 2 Diabetic Patients on Intracellular Lipid Content in Liver and Skeletal Muscle Diabetes, October 1, 2002; 51(10): 3025 - 3032. [Abstract] [Full Text] [PDF]

				C. Kohl, D. Ravel, J. Girard, and J.-P. Pegorier Effects of Benfluorex on Fatty Acid and Glucose Metabolism in Isolated Rat Hepatocytes: From Metabolic Fluxes to Gene Expression Diabetes, August 1, 2002; 51(8): 2363 - 2368. [Abstract] [Full Text] [PDF]

				P. Singhal, A. Caumo, P. E. Carey, C. Cobelli, and R. Taylor Regulation of endogenous glucose production after a mixed meal in type 2 diabetes Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E275 - E283. [Abstract] [Full Text] [PDF]

				G. F. Lewis, A. Carpentier, K. Adeli, and A. Giacca Disordered Fat Storage and Mobilization in the Pathogenesis of Insulin Resistance and Type 2 Diabetes Endocr. Rev., April 1, 2002; 23(2): 201 - 229. [Abstract] [Full Text] [PDF]

				M. Ciampelli, F. Leoni, F. Lattanzi, M. Guido, R. Apa, and A. Lanzone A pilot study of the long-term effects of acipimox in polycystic ovarian syndrome Hum. Reprod., March 1, 2002; 17(3): 647 - 653. [Abstract] [Full Text] [PDF]

				M. Segerlantz, M. Bramnert, P. Manhem, E. Laurila, and L. C. Groop Inhibition of the Rise in FFA by Acipimox Partially Prevents GH-Induced Insulin Resistance in GH-Deficient Adults J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5813 - 5818. [Abstract] [Full Text] [PDF]

				M. Ciampelli, G. Muzj, F. Leoni, D. Romualdi, C. Belosi, R. M. Cento, and A. Lanzone Metabolic and Endocrine Consequences of Acute Suppression of FFAs by Acipimox in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5324 - 5329. [Abstract] [Full Text] [PDF]

				R. Bergeron, S. F. Previs, G. W. Cline, P. Perret, R. R. Russell III, L. H. Young, and G. I. Shulman Effect of 5-Aminoimidazole-4-Carboxamide-1-{beta}-D-Ribofuranoside Infusion on In Vivo Glucose and Lipid Metabolism in Lean and Obese Zucker Rats Diabetes, May 1, 2001; 50(5): 1076 - 1082. [Abstract] [Full Text]

				W. Wang, A. Basinger, R. A. Neese, M. Christiansen, and M. K. Hellerstein Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women Am J Physiol Endocrinol Metab, July 1, 2000; 279(1): E50 - E59. [Abstract] [Full Text] [PDF]

				M. Krebs, H. Stingl, P. Nowotny, D. Weghuber, M. Bischof, W. Waldhausl, and M. Roden Prevention of in Vitro Lipolysis by Tetrahydrolipstatin Clin. Chem., July 1, 2000; 46(7): 950 - 954. [Abstract] [Full Text] [PDF]

				R. H. McCall, S. R. Wiesenthal, Z. Q. Shi, K. Polonsky, and A. Giacca Insulin acutely suppresses glucose production by both peripheral and hepatic effects in normal dogs Am J Physiol Endocrinol Metab, February 1, 1998; 274(2): E346 - E356. [Abstract] [Full Text] [PDF]